AdvanCell Enters Into Strategic Collaboration with Lilly to Advance Novel Targeted Alpha Therapies for the Treatment of Cancer
AdvanCell
Biotechnology Research
Sydney, New South Wales 4,336 followers
Changing the Course of Cancer Treatment
About us
AdvanCell is a clinical stage radiopharmaceutical company developing an innovative pipeline of 212Pb-based Targeted Alpha Therapies for cancer patients. AdvanCell’s platform technology addresses the most significant challenge in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell’s novel drug discovery, preclinical processes, and state-of-the-art facilities leverage daily access to 212Pb, the ideal isotope for Targeted Alpha Therapy. For more information, please visit www.advancell.com.au
- Website
-
http://www.advancell.com.au
External link for AdvanCell
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Sydney, New South Wales
- Type
- Privately Held
- Founded
- 2019
- Specialties
- Radiopharmaceuticals, Radioligand Discovery, 212Pb, Biotechnology, Biopharmaceuticals, and Changing the Course of Cancer
Locations
Employees at AdvanCell
Updates
-
Many thanks to the NYSE for acknowledging our US$112M Series C Financing #TargetedAlphaTherapy #BRI212NYC 🦘 ☢️ 🇦🇺 🇺🇲 AD⚡VC
-
-
A Big 🍎 THANK YOU to Nasdaq for recognising our Series C Financing #HeavyMetalTherapy #Lead212 #TargetedAlphaTherapy
-
-
🎸🔥 AdvanCell Successfully Completes an Oversubscribed US$112M Series C Financing. We are delighted to announce the successful completion of an oversubscribed Series C financing round, raising US$112 million. This funding fuels our mission to deliver life-changing Targeted Alpha Therapies, powered by Lead-212, the heavy metal of cancer care. 💪🎶 This milestone financing was co-led by SV Health Investors, Sanofi Ventures, Abingworth, and SymBiosis, with ongoing support from Morningside and new investors Tenmile and Brandon Capital and others🤘 AdvanCell has become a leader in radionuclide therapies, with compelling preclinical and clinical data validating our Pb-212 platform. With this funding, AdvanCell will: ✅ Expand our manufacturing capacity. ✅ Accelerate the clinical development of our therapeutic pipeline. ✅ Deliver heavy-hitting treatments for cancer patients. #TargetedAlphaTherapy #Radiopharmaceuticals #HeavyMetalScience #LeadTheWay #CancerResearch #MedicalInnovation #Oncology #HealthcareInvestment #LifeSciences #PatientCare #HeavyMetalTherapy #Run212theHills #BackInBlack #AD⚡️VC
-
AdvanCell reposted this
Looking forward to attending the #ASCOGenitourinaryCancersSymposium! We are proud to have our lead investigator Aaron Hansen present a #TrialinProgress poster on AdvanCell’s #TheraPb trial on February 13. My colleagues Paola Santoro, Megan Crumbaker, Gary L., Matthew Vincent and I are excited to see many of you at #GU25 in #SanFrancisco!
-
-
AdvanCell reposted this
We are excited to host the second PSMA PET conference with UCLA and the Prostate Cancer Foundation in March. The abstract deadline is January 10th (https://lnkd.in/gUJjy9sK). We have an incredible line up of speakers from across the globe (https://lnkd.in/gm-7WZfr). Please join us!
-
-
AdvanCell reposted this
Please help me spread the word! The Medicinal Molecules and Materials group at QUT are seeking an enthusiastic inorganic chemist/material scientist to join an ARC Linkage Project with AdvanCell, looking at characterising ceramic materials used in radio-pharmaceutical generation. Two year position based at QUT in Brisbane. Please share with your networks.
Postdoctoral Fellow Job in Brisbane QLD - SEEK
seek.com.au
-
Very happy to collaborate with our friends at Thor Medical ASA. Brede Høyland Ellingsæter Sindre Hassfjell Jasper C. Kurth OSL->BNE God Jul!
Big news just in time for the holiday season!🎁🎅 Thor Medical and AdvanCell sign strategic supply agreement for Thorium-228 📝 AdvanCell is an Australian-based clinical-stage radiopharmaceutical company and the agreement represents revenues of approximately NOK 100 million for Thor Medical over a five-year term. The agreement follows successful deliveries and confirmation of the performance of Thorium-228 product samples from the Herøya Industripark AS pilot facilities to AdvanCell earlier this year, notably, the first samples shipped from Thor Medical's newly commissioned pilot facilities. "The agreement demonstrates the increasing market needs for our products and supports our goal of bringing alpha emitters to market at scale as quickly as possible. The agreement marks another milestone towards a final investment decision for our AlphaOne plant in the first quarter 2025", says Jasper C. Kurth, CEO of Thor Medical. The AdvanCell agreement represents Thor Medical's third commercial supply agreement this year. “This agreement with Thor Medical is a significant step forward in securing the reliable supply of Thorium-228, a critical component for our Pb-212-based therapies. It reflects the strong mutual respect and shared commitment between our companies to innovation in radiopharmaceuticals”, says Andrew Adamovich, CEO of AdvanCell. Check out the full release 👉 https://lnkd.in/duykc62z
-
-
AdvanCell reposted this
Congratulations to winners of our 2024 OneTRI Awards, recognising people who embody our values of leadership, integrity, knowledge, excellence and collaboration – and our culture of partnership, support, diversity and inclusion. The winners for 2024 are: - OneTRI Unsung Hero, demonstrating excellence in leadership and support of research: TRI Engagement Managers Glenda Colburn, Julia Renaud and Benedette Watson - Discovery Platforms, for implementing novel approaches and technologies to enhance research: Professor Ranjeny Thomas from The University of Queensland #FrazerInstUQ. - Connecting with the Clinic, for leading collaborations between researchers and healthcare partners: Professor Josephine Forbes from Mater Research - Developing and/or Manufacturing Diagnostics and Therapeutics, demonstrating evidence of progression: the Vaxxas team - Clinical Trial and Industry Growth, leading to development, impact and outcomes: AdvanCell - OneTRI Award, for excellence in collaboration, contributing to a welcoming workplace and exemplifying TRI values: Michelle Spraggon. Pictured are the recipients in attendance and award presenters.
-